Mapping EQ-5D utilities to GBD 2010 and GBD 2013 disability weights: results of two pilot studies in Belgium

Maertens de Noordhout, C.; Devleesschauwer, B.; Gielens, L.; Plasmans, M. H. D.; Haagsma, J. A.; Speybroeck, N.

doi:10.1186/s13690-017-0174-z

Archives of Public Health

Table 2 Utilities by studies

From: Mapping EQ-5D utilities to GBD 2010 and GBD 2013 disability weights: results of two pilot studies in Belgium

ID	Health states	Mean Utility study 1	SD Utility study 1	Mean Utility study 2	SD Utility study 2	DW2010	DW2013
1	Fractures, treated (long term)	0.667	0.131	0.694	0.130	0.003	0.005
2	Distance vision, mild			0.826	0.154	0.004	0.003
5	Anemia, mild			0.813	0.138	0.005	0.004
8	Amputation of toe			0.650	0.127	0.008	0.006
11	Asthma, controlled			0.809	0.128	0.009	0.015
22	Claudication			0.644	0.177	0.016	0.014
29	Stroke, long term mild			0.550	0.168	0.021	0.019
37	Disfigurement, level 1 with itch or pain			0.639	0.177	0.029	0.027
47	Fracture of foot bones (long term, without treatment)			0.615	0.151	0.033	0.026
55	Headache tension type	0.530	0.169	0.350	0.204	0.040	0.037
60	Amputation of both legs (long-term with treatment)			0.304	0.244	0.051	0.088
77	Injured nerves (short term)			0.553	0.193	0.065	0.100
96	Fracture tibia, patella (short term)			0.389	0.170	0.087	0.050
107	Musculoskeletal problems (arms moderate)			0.474	0.173	0.114	0.117
111	Severe wasting	0.474	0.204	0.486	0.263	0.127	0.128
149	Crohn’s disease			0.455	0.200	0.225	0.231
155	Parkinson’s disease moderate			0.391	0.201	0.263	0.267
161	Gout, acute			0.193	0.212	0.293	0.295
174	Severe chest injury (short term, with or without treatment)			0.331	0.201	0.352	0.369
186	Fracture of pelvis short term			0.106	0.203	0.390	0.279
193	Headache (migraine)			0.548	0.194	0.433	0.441
200	Rectovaginal fistula			0.449	0.217	0.492	0.501
203	Terminal phase, without medication (for cancers, end-stage kidney/liver disease)			0.317	0.225	0.519	0.569
206	AIDS cases (not received ARV treatment)			0.360	0.228	0.547	0.582
214	Traumatic brain injury (long-term consequences)			0.200	0.257	0.625	0.637
219	Multiple sclerosis (severe)			0.144	0.198	0.707	0.719
220	Schizophrenia, acute	0.289	0.203	0.341	0.192	0.756	0.778

Back to article page

ISSN: 2049-3258

Contact us

General enquiries: journalsubmissions@springernature.com